15 Jul 2026
Appointment of Chairperson and Chief Executive Officer Ferozsons Laboratories Limited has announced the appointment of Mrs. Amna Piracha Khan as Chairperson of the Board and the reappointment of Mr. Osman Khalid Waheed as Chief Executive Officer, following the recent election of directors at the Extraordinary General Meeting. Material 15 Jul 2026
Approval of Annual Budget for FY 2026-27 The Board of Directors of Ferozsons Laboratories Limited has approved the company's annual budget for the fiscal year 2026-27 during their meeting held on July 14, 2026. OTHERS 07 Jul 2026
Board Meeting Other Than Financial Results Ferozsons Laboratories Limited has announced a board meeting scheduled for July 14, 2026, to discuss key governance matters including the election of the Chairman, appointment of the Chief Executive, constitution of board committees, and approval of the annual budget for FY2027. A closed period has been declared from July 7 to July 14, 2026. Meetings 03 Jul 2026
Certified True Copy of Resolution passed by the Shareholders in EOGM of the Company held on July 03, 2026 Ferozsons Laboratories Limited held an Extraordinary General Meeting (EOGM) on July 03, 2026, where shareholders confirmed the minutes of the 69th Annual General Meeting and elected seven directors for a three-year term starting July 07, 2026. OTHERS 24 Jun 2026
Election of Directors Ferozsons Laboratories Limited has announced the election of seven directors for a three-year term commencing July 07, 2026. As the number of candidates did not exceed the number of available board seats, these individuals are deemed elected unopposed. Material 19 Jun 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations Mr. Shahid Anwar, a Non-Executive Director of Ferozsons Laboratories Limited, purchased 100 shares of the company at a price of 406.50 per share on June 19, 2026. Insiders 19 Jun 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations Ferozsons Laboratories Limited reported that Independent Director Suleman Ghani purchased 1 share of the company at a price of 410.00 on June 19, 2026. Insiders 19 Jun 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations Mr. Shahid Anwar, a Non-Executive Director of Ferozsons Laboratories Limited, purchased 100 shares of the company at a price of 406.50 per share on June 19, 2026. Insiders 12 Jun 2026
Notice of Extraordinary General Meeting Ferozsons Laboratories Limited has issued a notice for an Extraordinary General Meeting (EOGM) to be held on July 03, 2026. The primary agenda is the election of seven directors for a three-year term following the passing of the Chairperson, Mrs. Akhter Khalid Waheed. Material 11 Jun 2026
Notice of Extraordinary General Meeting prior to publication Ferozsons Laboratories Limited has issued a notice for an Extraordinary General Meeting (EOGM) scheduled for July 3, 2026. The primary agenda includes the election of seven directors for a three-year term and the confirmation of minutes from the previous annual general meeting. Meetings 02 Jun 2026
Intimation of Passing Away of Mrs. Akhter Khalid Waheed, Chairperson and Director Ferozsons Laboratories Limited has announced the passing of its Chairperson and Director, Mrs. Akhter Khalid Waheed. The company stated that the resulting casual vacancy on the Board of Directors will be filled in accordance with regulatory requirements. Material 30 Apr 2026
Transmission of Quarterly Report for the Period Ended 31-03-2026 Ferozsons Laboratories Limited reported strong consolidated financial results for the nine months ended 31 March 2026, with net sales growing by 27% to Rs. 18.17 billion and profit after tax rising to Rs. 919.68 million. The company's performance was supported by volume-led growth in generic sales, although export sales were adversely affected by the closure of the Afghan border. Financials 29 Apr 2026
Financial Results for the Quarter Ended 31-03-2026 Ferozsons Laboratories Limited reported a strong performance for the nine months ended 31 March 2026, with consolidated profit after tax rising to PKR 919.68 million from PKR 666.38 million in the same period last year. Revenue also showed significant growth, reaching PKR 18.17 billion compared to PKR 14.35 billion in the prior year. Financials 22 Apr 2026
Board Meeting Ferozsons Laboratories Limited has scheduled a board meeting for April 29, 2026, to review the quarterly financial results for the period ending March 31, 2026, and to consider any potential dividend or other entitlements. Meetings 22 Apr 2026
Board Meeting Ferozsons Laboratories Limited has scheduled a Board of Directors meeting for April 29, 2026, to review the quarterly financial results for the period ending March 31, 2026, and to consider any potential dividend or other entitlements. Meetings 27 Feb 2026
Transmission of Quarterly Financial Statements for the Period Ended 31-12-2025 Financials 26 Feb 2026
Financial Results for the Quarter Ended 31-12-2025 Financials 19 Feb 2026
Board Meeting Meetings 19 Feb 2026
Board Meeting Meetings 19 Dec 2025
Change of Chief Financial Officer OTHERS 
